Daniel J Landsburg, MD

Associate Professor of Clinical Medicine (Hematology-Oncology)
Medical Director, Infusion Services, Hospital of the University of Pennsylvania
Faculty Leader, Hematology/Oncology Fellowship Quality Improvement and Patient Safety Education, Hospital of the University of Pennsylvania
Faculty mentor, Department of Medicine Healthcare Leadership in Quality Residency Track, Hospital of the University of Pennsylvania
Physician Leader, Oncology Clinical Effectiveness Team, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard
Philadelphia, PA 19104
Perelman Center for Advanced Medicine
12th Floor, South Pavilion
Office #12-182
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-615-7361
Fax: 215-615-5888
Fax: 215-615-5888
Education:
BA
University of Pennsylvania, 2004.
MD
Temple University School of Medicine, 2008.
Permanent linkBA
University of Pennsylvania, 2004.
MD
Temple University School of Medicine, 2008.
Description of Clinical Expertise
B cell lymphomaHodgkin lymphoma
Autologous stem cell transplantation
CART-19 therapy
Description of Other Expertise
Clinical operationsQuality improvement
Patient safety
Description of Research Expertise
Therapy for large B cell lymphomaMolecular classification of large B cell lymphoma
CART-19 therapy
Selected Publications
Landsburg DJ, Frigault MJ, Heim M, Foley SR, Hill B, Schofield G, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah G, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini M, Turtle CJ.: Real-world outcomes with tisagenlecleucel in aggressive B-cell lymphoma: subgroup analyses from the CIBMTR registry. J Immunother Cancer 13(2): e009890, Feb 2025.Schneider M, Nasta SD, Barta SK, Chong EA, Svoboda J, Schuster SJ, Landsburg DJ.: Analysis of Histologic, Immunohistochemical and Genomic Features of Large B Cell Lymphoma Tumors May Predict Response to Polatuzumab Vedotin Based Therapy in Patients With Relapsed/Refractory Disease. Clin Lymphoma Myeloma Leuk 25(1): 45-51, Jan 2025 Notes: DOI: 10.1016/j.clml.2024.08.010
Maillie L, Nasta SD, Svoboda J, Barta SK, Chong EA, Garfall AL, Gill SI, Porter DL, Schuster SJ, Catania C, Frey NV, Landsburg DJ.: Prolonged Neurologic Symptoms Following Immune Effector Cell-Associated Neurotoxicity Syndrome in Patients With Large B-cell Lymphoma Treated With Chimeric Antigen Receptor-Modified T Cell Therapy. Transplant Cell Ther 00912-1.(25): S2666-6367, Jan 2025 Notes: DOI: 10.1016/j.jtct.2025.01.884
Landsburg, DJ: Improving Cure Rates for Patients with Newly Diagnosed Large B-Cell Lymphomas: Targeted Therapies for High-Risk Pathologic Subgroups as Defined by Clinical Laboratory Testing. Cancers (Basel) 17(1): 18, Dec 2024.
Frost, Benjamin F., Frey, Noelle, Hexner, Elizabeth O., Schuster, Stephen J., Nasta, Sunita D., Loren, Alison W, Svoboda, Jakub, Landsburg, Daniel J., Levine, Bruce, Fraietta, Joseph A., Melenhorst, J. Joseph, Veloso, Elizabeth, Hwang, Wei-Ting, June, Carl H., Porter, David L., Gill, Saar: Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy. Blood. American Society of Hematology Annual Meeting, San Diego, CA. 144(Supplement 1): 588-588, Dec 2024 Notes: "Poster Presentation"
Elghawy, O., Thomas, C. J., Carter, J. S., Landsburg, D. J., Svoboda, J., Kim, E., Rook, A., Chung, J., Plastaras, J. P., LaRiviere, M., Hubbeling, H., Chelius, M., Nasta, S. D., Chong, E. A., Schuster, S. J., Barta, S. K.: Single Institution Experience of Pembrolizumab for Patients with Relapsed or Refractory Mycosis Fungoides or Sezary Syndrome. Clinical Lymphoma Myeloma & Leukemia, American Society of Hematology Annual Meeting, San Diego, CA. 24: S522-S522, Dec 2024 Notes: "Poster Presentation"
Dave, Nikita, Carvajal, Veronica, Carter, Jordan, Tsai, Donald Edward, Schuster, Stephen J., Gerson, James, Barta, Stefan K., Svoboda, Jakub, Chong, Elise A., Landsburg, Daniel J., Nasta, Sunita D.: Outcomes in Primary CNS Lymphoma: A Single Institution Experience from the Abramson Cancer Center at the University of Pennsylvania. Blood, American Society of Hematology Annual Meeting, San Diego, CA. 144(Supplement 1): 1699-1699, Dec 2024 Notes: "Poster Presentation"
Carulli, Alison, Elliott, Hayden, Mangan, Brendan, Whittenburg, James, Chong, Elise A., Nasta, Sunita D., Svoboda, Jakub, Barta, Stefan K., Porter, David L., Carter, Jordan S., Cook, Michael Roderick, Hossain, Nasheed, Gill, Saar, Garfall, Alfred L., Catania, Christopher, Kucharczuk, Colleen R., Schuster, Stephen J., Frey, Noelle, Landsburg, Daniel J.: Comparison of CRS- and Icans-Related Outcomes for Large B Cell Lymphoma Patients Treated with Commercial Axicabtagene Ciloleucel with or without Prophylactic Dexamethasone. Blood, American Society of Hematology, San Diego, CA. 144(Supplement 1): 2275-2275, Dec 2024 Notes: "Poster Presentation"
Brooks, Taylor R., Zabor, Emily C., Bedelu, Yohana B., Dave, Nikita, Landsburg, Daniel J., Nedved, Adrienne N., Wang, Yucai, Reinert, Catherine, Major, Ajay, Sears-Smith, Megan, Ghosh, Nilanjan, Salafian, Kiarash, Ayers, Emily, Miller, Jordan, Grover, Natalie, Peterson, Chelsea, Khan, Cyrus, Bliven, Sean Patrick, Narkhede, Mayur S., Ho, Carrie I, Smith, Stephen D., Gibson, Alyssa, Kline, Justin, Sundaram, Suchitra, Brody, Joshua, Baron, Kelsey, Hu, Boyu, Trotier, Daniel, Pophali, Priyanka A., Yang, XI, Karimi, Yasmin H., McKenna, Marshall, Tiger, Yun Kyoung, Niu, Alex, Hernandez-Ilizaliturri, Francisco, Garza Morales, Rodolfo, Munoz, Javier, Chinyengetere, Fadzai, Dave, Sandeep, Abdel-Razeq, Nayef, Alhaj Moustafa, Muhamad, Caimi, Paolo F., Hill, Brian T.: Real-World Outcomes with Bispecific T-Cell Engagers (REALBiTE) for Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center, Retrospective Cohort Study. Blood, American Society of Hematology Annual Meeting, San Diego, CA. 144(Supplement 1): 111-111, Dec 2024 Notes: "Poster Presentation"
Barta, Stefan K., Ruella, Marco, Schuster, Stephen J., Svoboda, Jakub, Carter, Jordan, Chong, Elise A., Landsburg, Daniel J., Nasta, Sunita D., Thomas, Colin, Patel, Ruchi P., Ghilardi, Guido, Porazzi, Patrizia, Yang, Steven, Qian, Dean, Pajarillo, Raymone, Zhang, Yunlin, Nimmagadda, Aditya, Vu, Trang, Peddada, Lavanya, Snook, Adam E., Siciliano, Nicholas A., Mazanet, Rosemary: CD5-Deleted Chimeric Antigen Receptor Cells (Senza5™ CART5) to Enhance Immunotherapy Against T-Cell Non-Hodgkin Lymphoma: A First-in-Human Phase I Clinical Trial. Blood, American Society of Hematology Annual Meeting, San Diego, CA. 144(Supplement 1): 7221-7221, Dec 2024 Notes: "Poster Presentation"